Clinical trials: Kidney Disease
HLRCC, Sporadic Papillary Renal Cell Cancer
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Background: At the present time, there are no drugs that have been proven to work in patients with papillary kidney cancer that has spread (metastasized) beyond the kidneys.
- Trial name
- NCT01130519
- Testing
- Bevacizumab, Erlotinib
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
This phase II trial is studying how well tandutinib works in treating patients who have undergone surgery for metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00408902
- Testing
- tandutinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Kidney Disease, Cardiovascular Disease
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Death
- Trial name
- FAVORIT (NCT00064753)
- Testing
- High Dose Multivitamin, Low Dose Multivitamin
- Where
- 30 sites in United States, Brazil and 1 more
- Volunteers
- 4,110 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Diseases, Apolipoprotein L1
APOL1 Genetic Testing Program for Living Donors
Living donor (LD) kidney transplantation is the optimal treatment for patients with end-stage kidney disease (ESKD). However, LDs take on a higher risk of future ESKD themselves.
- Conditions
- Chronic Kidney Diseases, Apolipoprotein L1, Kidney Transplantation
- Trial name
- NCT04910867
- Testing
- Components of Genetic Counseling, APOL1 genetic testing, EHR integration
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- Northwestern University
Anemia, Chronic Renal Insufficiency
Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
This is a randomized, controlled, double-blind, multicenter multinational safety study involving about 300 predialysis patients aged 18 years or above suffering from anemia. Symptomatic anemia will be corrected by s.c.
- Trial name
- NCT00701714
- Testing
- HX575 recombinant human erythropoietin alfa, ERYPO
- Where
- 123 sites in Austria, Bulgaria and 8 more
- Volunteers
- 337 people
- Sponsor
- Sandoz
HCV Infection
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly GS-9857) in participants with severe renal impairment and matched healthy control participants.
- Trial name
- NCT02402452
- Testing
- Voxilaprevir
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
End Stage Renal Disease
Safety and Dose Finding Study of Xigris in Hemodialysis Patients
The purpose of the study is to assess the safety of Xigris (Drotrecogin alfa) as an anticoagulant at different dose levels during dialysis treatment in patients with End Stage Renal Disease (ESRD).
- Trial name
- Xigris1003 (NCT01227187)
- Testing
- Drotrecogin alfa activated (Xigris)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- George Washington University
Chronic Kidney Disease
Chronic Kidney Disease Among Frail Elderly
Chronic kidney disease is a common diagnosis in the elderly population and it is associated with significant morbidity and health care costs. The prevalence rates increase with age to about 40% for adults aged > 65 years.
- Trial name
- FRED-CKD (NCT02351349)
- Testing
- multidisciplinary intervention
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Sameena Iqbal
Advanced Non-Clear Cell Kidney Cancer
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
This research study is studying the combination of Atezolizumab and Bevacizumab as a possible treatment for Advanced Non-Clear Cell Kidney Cancer.
- Trial name
- NCT02724878
- Testing
- Bevacizumab, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Kidney Diseases, Inflammation
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial.
- Trial name
- RESCUE (NCT03926117)
- Testing
- Ziltivekimab
- Where
- 49 sites in United States
- Volunteers
- 264 people
- Sponsor
- Novo Nordisk A/S
SARS-CoV-2 Infection, Acute Kidney Injury
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+)…
- Trial name
- NIRVANA (NCT04818216)
- Testing
- Nicotinamide riboside
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Cystinuria
TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study
The goal of this research project is to establish that in short-term use, tolvaptan is a safe and potentially effective new therapy for cystinuria, by conducting a short-term pilot study of the safety and tolerability of this…
- Trial name
- TCUPS (NCT02538016)
- Testing
- Tolvaptan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Caleb Nelson
Secondary Hyperparathyroidism, Hemodialysis
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism
This study is a exploratory comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in chronic kidney disease participants receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT00990704
- Testing
- paricalcitol, maxacalcitol
- Where
- 14 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Abbott
Carcinoma, Renal Cell
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
The purpose of this study is to determine the effect of a sunitinib administration schedule 2/1 (2 weeks of treatment followed by 1 week without) compared to a schedule 4/2 (4 weeks of treatment followed by 2 weeks without) on…
- Trial name
- ASSET (NCT03109015)
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Duke University
Autosomal Dominant Polycystic Kidney, Hypertension
Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease
People with autosomal dominant polycystic kidney disease (ADPKD) develop high blood pressure and kidney disease. Previous studies have shown that a commonly occurring chemical, nitric oxide (NO), is reduced in ADPKD, and may…
- Conditions
- Autosomal Dominant Polycystic Kidney, Hypertension, Endothelial Dysfunction
- Trial name
- BEET-PKD (NCT05401409)
- Testing
- Beetroot juice, Nitrate-depleted beetroot juice
- Where
- 2 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Western Sydney Local Health District
Renal Impairment
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment
This study will be conducted to assess the effect of severe renal impairment on the pharmacokinetics of lemborexant after a single-dose administration.
- Trial name
- NCT03443063
- Testing
- Lemborexant
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Chronic Kidney Diseases
DDEP for Lifestyle Modification in Chronic Kidney Disease
This is a randomized controlled feasibility trial conducted on patients with Chronic Kidney Disease (CKD) and their significant other
- Trial name
- NCT06226649
- Testing
- Digital Dyadic Empowerment
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Cheng Kung University
Acute Kidney Injury, Exercise-associated Hyponatremia
Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances
The specific aim of this study is to evaluate the safety of non-steroidal anti-inflammatory drugs (NSAIDs) and their impact on renal function and/or contribution to exercise-associated hyponatremia (EAH) during an ultramarathon…
- Conditions
- Acute Kidney Injury, Exercise-associated Hyponatremia, Perceived Exertion
- Trial name
- NAKED (NCT02272725)
- Testing
- Ibuprofen
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Stanford University
Carcinoma, Renal Cell
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
This is a Phase 3, open-label, randomized, controlled, multi-national, multi-center, parallel-arm study comparing tivozanib to sorafenib in participants with refractory advanced renal cell carcinoma (RCC).
- Trial name
- NCT02627963
- Testing
- Tivozanib hydrochloride, Sorafenib
- Where
- 191 sites in United States, Belgium and 10 more
- Volunteers
- 350 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Ureteral Calculi, Kidney Stones
Study of Silodosin to Facilitate Passage of Urinary Stones
The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
- Conditions
- Ureteral Calculi, Kidney Stones, Urolithiasis
- Trial name
- NCT01144949
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 239 people
- Sponsor
- Watson Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.